← All trials
NCT04362527
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2020
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- Apr 27, 2020
- Last posted
- Apr 27, 2020
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of AngersLead sponsor
- University of Western BrittanyOverall official - principal investigator
- University Hospital, ToursOverall official - principal investigator
- University of StrasbourgOverall official - principal investigator
- University Clermont AuvergneOverall official - principal investigator
- University of MontpellierOverall official - principal investigator
- APHP - Hôpital NeckerOverall official - principal investigator
- Central Hospital, Dijon, FranceOverall official - principal investigator
- University of NantesOverall official - principal investigator
- University of PoitiersOverall official - principal investigator
- University of RennesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.